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FORENSIC PATHOLOGY. CASE REPORTS
Acute myocardial infarction following off label retrobulbar injection of 
desmopressin for non-arteritic anterior ischemic optic neuropathy (NAION). 
Causal correlation or coincidence?
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 Abstract: A 60-year-old man, apparently healthy with negative history for cardiovascular diseases, was hospitalized 
because of an unilateral sudden and painless severe visual loss. Diagnosis of NAION was made. Two separate and immediately 
consecutive injections of betamethasone (2 mg/0.5 mL) and desmopressin (2 mcg/0.5 mL) were performed in the retrobulbar 
space. Fifteen minutes later, the patient suddenly developed cold sweat, dyspnoea, thoracic pain and severe hypotension. Acute 
myocardial infarction was diagnosed by ECG. Desmopressin was the probable causative agent. Thrombotic events following 
intravenous or oral administration of desmopressin have been documented in the medical literature. To the best of our knowledge 
this is the first case in which a thrombotic event was associated with the retrobulbar route.  
 Retrobulbar desmopressin administration in patients with NAION can be probably associated with AMI. Considering its 
invasiveness and the unproven benefit in the treatment of NAION, this therapeutic approach can not be currently recommended.
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INTRODUCTION
 Off-label use of a drug refers to the administration 
of a registered medicine in a clinical setting or for 
achieving a therapeutical goal that are not disclaimed in 
the summary of product characteristics. Examples include 
use in a indication, patient age range, dose or route, 
different to that approved by regulatory authorities [1]. 
Studies in the United States have shown that off-label use 
may account for approximately 20% of prescriptions, or 
150 million prescriptions per year [2]. While off label 
prescribing is not illegal, and may sometimes be clinically 
appropriate, it brings with it, a number of clinical, safety 
and ethical issues [3]. 
 Non-arteritic anterior ischemic optic 
neuropathy (NAION) is a multifactorial disease with 
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several risk factors including diabetes, hypertension and 
hypercholesterolemia [4]. Other associations have been 
suggested or identified, including nocturnal hypotension, 
anemia, hyperhomocysteinemia, obstructive sleep apnea 
syndrome, and some coagulopaties [5]. Most cases of 
NAION occurs in patients older than 55 years. The 
majority have underlying systemic vascular disease, 
although this may be undiagnosed at the time of onset [6].
 Small vessel circulatory insufficiency of the optic 
nerve head is the most widely accepted pathophysiology 
of NAION, but the location of the associated vasculopathy 
and the mechanism of ischemia remain uncertain. 
NAION is characterized histologically by ischemia at the 
level of the prelaminar/laminar portions of optic nerve 
supplied by the circle of Zinn-Haller via short posterior 
ciliary arteries [7].
 A number of treatments for NAION have been 
attempted, but the evidence of beneficial effects of some 
of these therapeutic approaches remains weak [8]. We 
describe a fatal case of acute myocardial infarction 
(AMI) in patients receiving retrobulbar injection of 
bethametasone and desmopressin for the treatment of 
NAION. Notably, clinicians managing the present case 
adopted an off-label use of a drug without approval of 
the Ethics Committee. Due to the ethical and legal 
implication, the present case was evaluated by the Unit 
of Forensic Medicine in collaboration with the Unit of 
Adverse Drug Reaction Monitoring.
CASE REPORT
 A 60-year-old man, apparently healthy with 
no history of cardiovascular diseases, was hospitalized 
because of an unilateral sudden and painless severe 
visual loss (20/200), on waking in the morning. The optic 
disc appeared hyperaemic and oedematous, with a focal 
severe swelling. Relative inferior altitudinal scotoma was 
present at visual field examination. The patient presented 
with erythrocyte sedimentation rate 20 mm/h and normal 
levels of plasma fibrinogen and C-reactive protein. 
The diagnosis of NAION was made. Two separate and 
immediately consecutive injections of betamethasone 
(2 mg/0.5 mL) and desmopressin (2 mcg/0.5 mL) were 
performed in the retrobulbar space. The administration 
of any pre-treatment medication, or cardiovascular 
examination are not documented. In the patient medical 
records, the total volume of the injections and the size 
of the needle used are not specified. The procedure was 
technically uncomplicated without any monitoring in 
progress during injections such as ECG, peripheral 
oxygen saturation, or blood pressure measurement. About 
twenty minutes later, the patient suddenly developed 
cold sweat, dyspnoea, thoracic pain, severe hypotension 
and ST segment elevation. Acute myocardial infarction 
(AMI) was diagnosed in spite of cardiac troponin and 
CK-MB resulted negative. Although intensive supportive 
care was started, the patient became unconsciousness 
and developed cardiac arrest. Despite cardiopulmonary 
resuscitation, the patient died of irreversible cardio-




 Heart presented a normal shape and weight 
(350g); first tract of left anterior descending coronary 
artery showed an atherosclerotic narrowing complicated 
by thrombosis of the left anterior descending artery, 
located 2 cm after its origin.
 Examination of the other organs was 
unremarkable, except for pulmonary edema and 
polyvisceral stasis. There was no evidence of increased 
orbital volume or sign of vagal compression secondary to 
retrobulbar haemorrhage.
 Cardiac specimens were obtained from right 
ventricular free wall; ventricular septum (anterior and 
posterior); anterior, lateral, and posterior left ventricular 
free wall, and apex. 
 Histological examination of the heart 
(Ematossiline&Eosine, trichrome stain)  showed absence 
of cardiac ischemic findings (such as elongation of 
sarcomeres, nuclei contraction band necrosis, myofiber 
eosinophilia, etc.).
 Anterior descending coronary artery showed 
endoluminal thrombosis. At this level Ematossilin&Eosin, 
trichrome stain and immunofluorescence (IF) utilizing 
fluorescente-labeled antibodies to detect fibrinogen, have 
been performed. 
 Microscopic findings of endoluminal thrombus 
showed signs coherent a very recent age of coronary 
thrombus. It was composed by irregular platelets 
reticular, erythrocytes and granulocytes (Figs 1A and 
1B). Immunofluorescence stain resulted positive for 
fibrinogen (Fig. 2). 
RESULTS AND DISCUSSION
 In the present case, an off label retrobulbar 
injection of desmopressin and betamethasone was 
followed by the development of AMI. 
 Diagnosis of AMI outcomes from a strong 
correlation among clinical, strumental and autoptic 
data. ECG was performed with a ST elevation, cardiac 
troponine and CK-MB were unremarkable just as 
microscopic myocardial examination. This result was 
expected in relation to a shorter period of survival.
 It’s important to remember that the death has 
been declared about fifty minutes after the beginning 
of the heart attack. Notoriously, this shorter period to 
determine myocardium alterations microscopically 
detectable.
 Ematossilin&Eosin in addition to IF have been 
useful to individuate the typical components of an early 
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stage thrombus, with particular regard for fibrinogen. The 
detection of this one was coherent with the chronology of 
the events [18]. 
 The plausible temporal association between 
desmopressin administration and the development 
of AMI and the unlikely alternative etiology strongly 
support a causal relationship.
 Desmopressin is a synthetic replacement for 
vasopressin, indicated for treatment of diabetes insipidus 
and nocturnal enuresis, due to its specific antidiuretic 
effect. It is also indicated  for the treatment of mild 
haemophilia and type 1 von Willebrand (vW) disease, 
due to its ability of increasing plasma Factor VIII 
(FVIII) and vW Factor (vWF). It may be taken nasally, 
subcutaneously, intravenously, or as an oral or sublingual 
tablet [9, 10].
 The potential for thrombotic events associated 
with the use of intravenous administration of 
desmopressin have been reported since the 80’s and 
includes cerebrovascular accident, [11] coronary 
syndromes [12] and myocardial infarction [13, 14]. 
A case of abdominal arterial thrombosis has been 
recently documented even after oral administration of 
desmopressin [15]. To the best of our knowledge this is 
the first case reported describing the development of a 
thrombotic event following retrobulbar administration 
of desmopressin in a patient with NAION.
 It is important to note that in the present case 
desmopressin was administered locally in lower doses 
(2 mcg) as compared to that (0.19 mcg/Kg, 30 minutes 
infusion) administered intravenously in previously 
reported cases of desmopressin-induced AMI [13]. 
Notably, AMI was reported even after a single test dose 
of desmopressin (0.19 mcg/Kg) [14]. 
 The mechanism of desmopressin-induced 
thrombotic events is probably represented by the 
increase of plasma levels of FVIII and vWF (3 to 5-fold 
both in healthy individuals and haemophilic patients), 
with the consequent increase of the risk of thrombotic 
complications [16].  It is reasonable to suppose that this 
risk of AMI would be particularly high in elderly and in 
patients with coronary heart disease. 
 Although in the present case the cardiovascular 
adverse event was facilitated by the asymptomatic arterial 
coronary disease of the patient, disclosed at autopsy, 
the most probable triggering cause of thrombotic event 
remains desmopressin. Among other potential causative 
agents, betamethasone and other corticosteroids have not 
usually associated with the development of thrombotic 
events. Finally, procedural complications (i.e. accidental 
endovenous injection with consequent thrombus 
development) have been ruled out by autoptic findings.
 Since an evidence-based effective standard 
treatment for NAION is not available to date, most 
therapeutic approaches are empirical and include a 
wide range of agents presumed to act on thrombosis, 
on the blood vessels, on the disk edema, or supposed to 
have a neuroprotective effect. Among other proposed 
Figure 1. A. Fresh thrombus in the left anterior descending coronary artery (Ematossilin & Eosin 2X magnification). 
B. A particular of fresh thrombus in the left anterior descending coronary artery showing erythrocytes, fibrin and granulocytes 
(Ematossilin & Eosin 10 X magnification).
Figure 2. Immunofluorescence stain strongly positive for 
fibrin in coronary thrombus (10 X magnification). 
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treatment retrobulbar injection of corticosteroid and 
desmopressin represents an invasive approach, with 
potential local and systemic complications, which, to 
the best of our knowledge, has never been documented 
before. The rationale of using desmopressin in the 
treatment of NAION is uncertain and consists probably in 
experimental findings demonstrating that desmopressin 
induces ciliary artery relaxation in dog models via 
vasopressin-1 receptors through a mechanism which 
involves nitric oxide [17]. In turn, this would enhance 
vascular permeability, thus facilitating the reabsorption 
of optic edema. A similar vasodilation effect can be 
attributed to corticosteroids [17].
 In the present case report desmopressin 
was used for the treatment of NAION although the 
rationale for its use was weak and the request for the 
off label administration was never transmitted to the 
local Ethics Committee.  Nevertheless, the observation 
derived from this reckless use allows to suggest that 
desmopressin is endowed with thrombotic potential 
even when administered retrobulbarily other than by the 
classic routes. This could be particularly true in patients 
with cardiovascular diseases. This treatment should 
be avoided until evidence of benefits (if any) will be 
available. Whenever effective, this off label use should be 
mandatorily authorized by an ethical committee.
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